SpaceX’s $75 billion IPO briefly lifted its market value past $2 trillion, fueled by Starlink’s growth and signaling a shift in competitive power across launch, satellite, and AI sectors.
SpaceX is entering a phase of rapid AI-driven revenue growth, with projections suggesting it could surpass $200 billion annually within two years, rivaling leading tech giants.
Once known for its eco-friendly sneakers, Allbirds has sold its footwear business and transformed into Smartbird, focusing entirely on AI infrastructure under new leadership.
Bungie faces rumored cuts affecting half its workforce after ending Destiny 2 development and struggling with Marathon, despite Destiny 2’s Steam sales rebound.
Chinese AI startup DeepSeek has raised $7.4 billion, pushing its valuation past $50 billion and positioning it as the country's most valuable AI company.
HSBC advances its artificial intelligence capabilities with Google Cloud to boost wealth management, enhance financial-crime controls, and accelerate decision-making across its operations.
Insurance mergers and acquisitions continue actively, with AI-driven innovation shaping deal strategies and influencing valuations across the sector.
Netflix is reportedly among companies interested in acquiring Lionsgate, aiming to add iconic franchises and a theme park to its growing entertainment portfolio.
The $22 billion deal between Fox and Roku highlights growing media consolidation with focus on streaming reach, leaving creators’ opportunities and content distribution mostly stable for now.
A former Republican operative claims the Trump administration’s endorsement of the Paramount Skydance-Warner Bros. Discovery merger risks relocating major operations out of California, threatening the state’s economy.
As AI demand skyrockets, data centers face a critical energy shortage that threatens to stall growth, spotlighting a lesser-known company positioned to tackle this challenge.
Novo Nordisk plans to seek regulatory approval for its oral Wegovy in China soon, intensifying competition with Eli Lilly in the country’s growing obesity drug sector.